Sai Life Sciences Block Deal: TPG Asia to Offload 6% Stake Worth $102 Million

On June 20, 2025, Sai Life Sciences shares are in focus as the private equity giant TPG Asia is reportedly set to sell a 6% stake in the company, through a block deal, as mentioned in the CNBC-TV18 news report.

Sai Life Sciences Block Deal Details

The planned transaction will see the sale of approximately 12.5 million shares at a base price of ₹710 per share, representing a 2.5% discount to the current market price. The total deal value is expected to be around $102 million. As per the deal terms, the seller will be subject to a 60-day lock-in period post-sale.

This development comes on the heels of Sai Life Sciences’ bullish growth outlook. In a recent update, the company projected a compound annual growth rate (CAGR) of 15–20% in revenues over the next 3–5 years, alongside an expansion in EBITDA margins from the current 24% to as high as 30%.

Management Take on Business Growth

Commenting on the growth trajectory, Siva Chittor, Chief Financial Officer of Sai Life Sciences, said, “A large portion of this will come from operating leverage on a counter expansion in the business. That is really what we are seeing today. If you look at what we did last year, we were a little about 20%, and then we ended this year at 25%.

” He said achieving 20% compound annual growth in revenue and 25% in EBITDA is possible, but growth in the CDMO sector tends to be uneven. Some years may see slower momentum, while others could deliver stronger results.

In its latest financials for the January–March 2025 quarter (Q4FY25), Sai Life Sciences posted a revenue of ₹579 crore, an EBITDA margin of 27.2%, and a net profit of ₹88 crore.

Also Read: M&M Boosts Stake in Mahindra Lifespaces to 52.43% Through ₹257 Rights Issue

About Sai Life Sciences Limited

Sai Lifesciences provides end-to-end contract research, development, and manufacturing services to biotech and global pharmaceutical clients. With facilities across India, the US, and the UK, Sai Life Sciences currently serves over 280 clients, including 18 of the world’s top 25 pharma companies.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.